Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nedaplatin and S-1 as postoperative adjuvant therapy for advanced oral cancer
ChiCTR2100049396Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, nedaplatin and tegafur in mouth cancer and Oral Mucosal Carcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 1-year disease-free survival rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
camrelizumabnedaplatintegafur
03
Conditions
mouth cancerOral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2100049396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049396.